Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | WEE1 | P30291 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553656 | 0.88 | RIPK2 (0.38) | RIPK2ACVR1NOD2JAK2TBK1 | |
| SCHEMBL15785229 | 0.79 | TNK2 (0.39) | TNK2WEE1FGFR1SRCPDGFRB | |
| SCHEMBL15036016 | 0.78 | TNK2 (0.40) | TNK2WEE1SRCPAK4PKN1 | |
| SCHEMBL15041896 | 0.78 | TNK2 (0.39) | TNK2WEE1SRCPAK4PKN1 | |
| SCHEMBL15041238 | 0.77 | PAK1 (0.39) | TNK2FGFR1SRCFGFR4CDK4 | |
| SCHEMBL14682000 | 0.74 | RIPK2 (0.42) | RIPK2ACVR1NOD2TNK2WEE1 | |
| SCHEMBL15036132 | 0.71 | TNK2 (0.41) | TNK2SRCCDK4CCND1CCND2 | |
| SCHEMBL14681991 | 0.71 | PRKCZ (0.40) | RIPK2ACVR1NOD2TNK2FGFR1 | |
| SCHEMBL13553731 | 0.71 | JAK3 (0.42) | TNK2JAK3WEE1FGFR1SRC | |
| SCHEMBL15035102 | 0.71 | TNK2 (0.42) | TNK2SRCPAK4PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | RIPK2 971/4885ACVR1 4752/4885NOD2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.